The generic drug, montelukast should be offered to people ahead of combination inhalers such as GlaxoSmithKline's Seretide, in a bid to save the NHS millions of pounds, according to draft guidance ...

Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.